Kwan, E. M.
Thangasamy, I. A.
Teh, J.
Alghazo, O.
Sathianathen, N. J.
Lawrentschuk, N.
Azad, A. A.
Funding for this research was provided by:
National Health and Medical Research Council (APP1133107)
Victorian Cancer Agency
Astellas Pharma US
Article History
Received: 30 July 2019
Accepted: 15 December 2019
First Online: 2 January 2020
Compliance with ethical standards
:
: Edmond M Kwan has received honorarium from Janssen; research funding from Astellas Pharma and AstraZeneca; travel / accommodation from Astellas Pharma, Pfizer and Ipsen. Arun A Azad is a consultant for Astellas, Janssen and Novartis; is on the speakers bureau for Astellas, Janssen, Novartis and Amgen; has received honorarium from Astellas Pharma, Janssen, Novartis, Tolmar, Amgen, Pfizer and Telix; on the member of the scientific advisory board for Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer and Telix; research funding from Astellas Pharma and Merck Serono. All authors declare no conflicts of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: This article does not contain any studies with human participants. Therefore, issues of informed consent are not applicable.